Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 COMT 4件: Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00781 Entacapone 2件: 6, 17
2 COMT 4件: Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00786 Tolcapone 3件: 6, 28, 127
3 COMT 4件: Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D10825 Opicapone 1件: 6
4 MAPK14 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod 2件: 113, 222
5 MAPK14 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod 1件: 8
6 DDC 6件: Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse D00558 Carbidopa 9件: 2, 4, 6, 13, 17, 90, 140, 164, 201
7 DDC 6件: Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse D03082 Benserazide 1件: 6
8 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00059 Levodopa 8件: 2, 4, 6, 17, 90, 140, 164, 201
9 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00502 Pergolide 1件: 6
10 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D00633 Dopamine 4件: 6, 7, 74, 299
11 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D01044 Flupentixol 1件: 97
12 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D02004 Apomorphine 3件: 5, 6, 7
13 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D07460 Apomorphine 3件: 5, 6, 7
14 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D07870 Dopamine 4件: 6, 7, 74, 299
15 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D08339 Pergolide 1件: 6
16 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D09886 Dexpramipexole 1件: 2
17 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D11431 Tavapadon 1件: 6
18 DRD1 5件: Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Morphine addiction D11839 Foslevodopa 1件: 6
19 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00059 Levodopa 8件: 2, 4, 6, 17, 90, 140, 164, 201
20 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00136 Haloperidol 1件: 8
21 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00270 Chlorpromazine 1件: 254
22 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00426 Risperidone 5件: 8, 156, 179, 187, 206
23 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00454 Olanzapine 2件: 2, 8
24 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00458 Quetiapine 2件: 6, 13
25 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00502 Pergolide 1件: 6
26 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00559 Pramipexole 3件: 2, 6, 20
27 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00560 Pimozide 1件: 2
28 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00633 Dopamine 4件: 6, 7, 74, 299
29 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00702 Buspirone 3件: 6, 51, 179
30 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00726 Metoclopramide 1件: 51
31 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00780 Bromocriptine 2件: 6, 74
32 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00784 Ropinirole 4件: 2, 6, 74, 309
33 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00789 Chlorpromazine 1件: 254
34 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00799 Trifluoperazine 2件: 283, 284
35 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D00987 Cabergoline 3件: 6, 74, 75
36 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01044 Flupentixol 1件: 97
37 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01164 Aripiprazole 2件: 6, 206
38 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01226 Sulpiride 5件: 2, 6, 17, 46, 70
39 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01348 Terguride 2件: 51, 86
40 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01448 Trifluoperazine 2件: 283, 284
41 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01462 Lisuride 2件: 6, 86
42 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01745 Domperidone 5件: 6, 13, 17, 51, 230
43 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D01898 Haloperidol 1件: 8
44 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D02004 Apomorphine 3件: 5, 6, 7
45 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D02213 Metoclopramide 1件: 51
46 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D03165 Bromocriptine 2件: 6, 74
47 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D03274 Chlorpromazine 1件: 254
48 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D04034 Chlorpromazine 1件: 254
49 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05008 Metoclopramide 1件: 51
50 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05575 Pramipexole 3件: 2, 6, 20
51 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D05768 Rotigotine 2件: 6, 127
52 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D06623 Olanzapine 2件: 2, 8
53 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07305 Piribedil 1件: 6
54 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07309 Melperone 1件: 6
55 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07460 Apomorphine 3件: 5, 6, 7
56 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07593 Buspirone 3件: 6, 51, 179
57 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07868 Domperidone 5件: 6, 13, 17, 51, 230
58 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D07870 Dopamine 4件: 6, 7, 74, 299
59 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08132 Lisuride 2件: 6, 86
60 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08339 Pergolide 1件: 6
61 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08456 Quetiapine 2件: 6, 13
62 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08489 Ropinirole 4件: 2, 6, 74, 309
63 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08549 Sulpiride 5件: 2, 6, 17, 46, 70
64 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08590 Tiapride 1件: 8
65 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D08636 Trifluoperazine 2件: 283, 284
66 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09397 Pardoprunox 1件: 6
67 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09886 Dexpramipexole 1件: 2
68 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09953 Pridopidine 3件: 2, 6, 8
69 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D09997 Cariprazine 1件: 21
70 DRD2 5件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease D11839 Foslevodopa 1件: 6
71 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa 8件: 2, 4, 6, 17, 90, 140, 164, 201
72 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine 2件: 2, 8
73 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole 3件: 2, 6, 20
74 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine 4件: 6, 7, 74, 299
75 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole 4件: 2, 6, 74, 309
76 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D01164 Aripiprazole 2件: 6, 206
77 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D01462 Lisuride 2件: 6, 86
78 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole 3件: 2, 6, 20
79 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D06623 Olanzapine 2件: 2, 8
80 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D07305 Piribedil 1件: 6
81 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine 4件: 6, 7, 74, 299
82 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride 2件: 6, 86
83 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole 4件: 2, 6, 74, 309
84 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D09397 Pardoprunox 1件: 6
85 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole 1件: 2
86 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa 1件: 6
87 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa 8件: 2, 4, 6, 17, 90, 140, 164, 201
88 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00283 Clozapine 1件: 6
89 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00454 Olanzapine 2件: 2, 8
90 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00559 Pramipexole 3件: 2, 6, 20
91 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine 4件: 6, 7, 74, 299
92 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00784 Ropinirole 4件: 2, 6, 74, 309
93 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D01462 Lisuride 2件: 6, 86
94 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D05575 Pramipexole 3件: 2, 6, 20
95 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D06623 Olanzapine 2件: 2, 8
96 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine 4件: 6, 7, 74, 299
97 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D08132 Lisuride 2件: 6, 86
98 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D08489 Ropinirole 4件: 2, 6, 74, 309
99 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole 1件: 2
100 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa 1件: 6
101 DRD5 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa 8件: 2, 4, 6, 17, 90, 140, 164, 201
102 DRD5 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00633 Dopamine 4件: 6, 7, 74, 299
103 DRD5 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D07870 Dopamine 4件: 6, 7, 74, 299
104 DRD5 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D09886 Dexpramipexole 1件: 2
105 DRD5 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D11431 Tavapadon 1件: 6
106 DRD5 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D11839 Foslevodopa 1件: 6
107 GRIA1 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
108 GRIA1 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
109 GRIA1 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel 2件: 2, 6
110 GRIA1 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel 3件: 2, 6, 144
111 GRIA2 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
112 GRIA2 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
113 GRIA2 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel 2件: 2, 6
114 GRIA2 10件: Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel 3件: 2, 6, 144
115 GRIA3 10件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
116 GRIA3 10件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
117 GRIA3 10件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D02696 Talampanel 2件: 2, 6
118 GRIA3 10件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Transcriptional misregulation in cancer D08964 Perampanel 3件: 2, 6, 144
119 GRIA4 7件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
120 GRIA4 7件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
121 GRIA4 7件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel 2件: 2, 6
122 GRIA4 7件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel 3件: 2, 6, 144
123 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
124 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
125 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine 4件: 6, 8, 13, 127
126 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
127 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate 2件: 6, 206
128 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
129 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
130 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
131 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate 2件: 6, 206
132 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine 3件: 2, 4, 70
133 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine 4件: 6, 8, 13, 127
134 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
135 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
136 GRIN2A 11件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine 1件: 8
137 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
138 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
139 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00777 Amantadine 4件: 6, 8, 13, 127
140 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
141 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D02780 Acamprosate 2件: 6, 206
142 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
143 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
144 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
145 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate 2件: 6, 206
146 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine 3件: 2, 4, 70
147 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine 4件: 6, 8, 13, 127
148 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
149 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
150 GRIN2B 12件: Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine 1件: 8
151 KCNJ3 8件: Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D00636 Amiodarone 2件: 28, 127
152 KCNJ3 8件: Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone 2件: 28, 127
153 KCNJ5 7件: Retrograde endocannabinoid signaling, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D00636 Amiodarone 2件: 28, 127
154 KCNJ5 7件: Retrograde endocannabinoid signaling, Serotonergic synapse, Dopaminergic synapse, Estrogen signaling pathway, Oxytocin signaling pathway, GnRH secretion, Morphine addiction D02910 Amiodarone 2件: 28, 127
155 MAOA 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D00505 Phenelzine 1件: 6
156 MAOA 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02561 Moclobemide 1件: 6
157 MAOA 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02579 Iproniazid 1件: 6
158 MAOA 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05458 Phentermine 1件: 97
159 MAOA 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05459 Phentermine 1件: 97
160 MAOA 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08349 Phenelzine 1件: 6
161 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D00505 Phenelzine 1件: 6
162 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D00785 Selegiline 1件: 6
163 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02562 Rasagiline 7件: 2, 5, 6, 13, 17, 58, 66
164 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D02579 Iproniazid 1件: 6
165 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D03731 Selegiline 1件: 6
166 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05458 Phentermine 1件: 97
167 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D05459 Phentermine 1件: 97
168 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08349 Phenelzine 1件: 6
169 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08469 Rasagiline 7件: 2, 5, 6, 13, 17, 58, 66
170 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10158 Safinamide 2件: 6, 17
171 MAOB 10件: Glycine, serine and threonine metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10829 Rasagiline 7件: 2, 5, 6, 13, 17, 58, 66
172 PPP3CA 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
173 PPP3CA 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
174 PPP3CA 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
175 PPP3CA 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
176 PPP3CA 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
177 PPP3CB 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
178 PPP3CB 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
179 PPP3CB 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
180 PPP3CB 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
181 PPP3CB 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
182 PPP3CC 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
183 PPP3CC 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00184 Cyclosporine 44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
184 PPP3CC 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D05480 Pimecrolimus 1件: 160
185 PPP3CC 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
186 PPP3CC 24件: MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09033 Voclosporin 1件: 222
187 MAPK11 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod 2件: 113, 222
188 MAPK11 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod 1件: 8
189 MAPK13 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod 2件: 113, 222
190 MAPK13 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod 1件: 8
191 MAPK12 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D09639 Losmapimod 2件: 113, 222
192 MAPK12 52件: Endocrine resistance, MAPK signaling pathway, Rap1 signaling pathway, FoxO signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Thermogenesis, Neurotrophin signaling pathway, Retrograde endocannabinoid signaling, Dopaminergic synapse, Inflammatory mediator regulation of TRP channels, GnRH signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D10959 Neflamapimod 1件: 8
193 SCN1A 1件: Dopaminergic synapse D00252 Carbamazepine 2件: 13, 231
194 SCN1A 1件: Dopaminergic synapse D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
195 SCN1A 1件: Dopaminergic synapse D00358 Lidocaine 13件: 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
196 SCN1A 1件: Dopaminergic synapse D00512 Phenytoin 1件: 13
197 SCN1A 1件: Dopaminergic synapse D00533 Oxcarbazepine 1件: 13
198 SCN1A 1件: Dopaminergic synapse D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
199 SCN1A 1件: Dopaminergic synapse D00538 Zonisamide 1件: 6
200 SCN1A 1件: Dopaminergic synapse D00636 Amiodarone 2件: 28, 127
201 SCN1A 1件: Dopaminergic synapse D00638 Flecainide 1件: 6
202 SCN1A 1件: Dopaminergic synapse D00639 Mexiletine 5件: 1, 2, 10, 113, 114
203 SCN1A 1件: Dopaminergic synapse D00642 Quinidine 3件: 2, 8, 13
204 SCN1A 1件: Dopaminergic synapse D00643 Quinidine 3件: 2, 8, 13
205 SCN1A 1件: Dopaminergic synapse D01287 Levobupivacaine 1件: 46
206 SCN1A 1件: Dopaminergic synapse D01450 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
207 SCN1A 1件: Dopaminergic synapse D01768 Oxybuprocaine 1件: 6
208 SCN1A 1件: Dopaminergic synapse D02086 Lidocaine 13件: 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
209 SCN1A 1件: Dopaminergic synapse D02103 Phenytoin 1件: 13
210 SCN1A 1件: Dopaminergic synapse D02272 Quinidine 3件: 2, 8, 13
211 SCN1A 1件: Dopaminergic synapse D02910 Amiodarone 2件: 28, 127
212 SCN1A 1件: Dopaminergic synapse D03492 Cibenzoline 1件: 58
213 SCN1A 1件: Dopaminergic synapse D04048 Ropivacaine 3件: 36, 46, 70
214 SCN1A 1件: Dopaminergic synapse D05775 Rufinamide 1件: 144
215 SCN1A 1件: Dopaminergic synapse D07552 Bupivacaine 8件: 46, 51, 53, 70, 96, 168, 226, 298
216 SCN1A 1件: Dopaminergic synapse D07962 Flecainide 1件: 6
217 SCN1A 1件: Dopaminergic synapse D08116 Levobupivacaine 1件: 46
218 SCN1A 1件: Dopaminergic synapse D08127 Lidocaine 13件: 6, 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
219 SCN1A 1件: Dopaminergic synapse D08215 Mexiletine 5件: 1, 2, 10, 113, 114
220 SCN1A 1件: Dopaminergic synapse D08319 Oxybuprocaine 1件: 6
221 SCN1A 1件: Dopaminergic synapse D08458 Quinidine 3件: 2, 8, 13
222 SCN1A 1件: Dopaminergic synapse D08490 Ropivacaine 3件: 36, 46, 70
223 SCN1A 1件: Dopaminergic synapse D11155 Eleclazine 1件: 58
224 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D00817 Bupropion 5件: 8, 18, 21, 96, 171
225 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D01296 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
226 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D03215 Armodafinil 3件: 6, 13, 84
227 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D04999 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
228 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05458 Phentermine 1件: 97
229 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D05459 Phentermine 1件: 97
230 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07591 Bupropion 5件: 8, 18, 21, 96, 171
231 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D07938 Bupropion 5件: 8, 18, 21, 96, 171
232 SLC6A3 4件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases D08130 Lisdexamfetamine 1件: 13
233 SLC18A2 4件: Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D08575 Tetrabenazine 1件: 8
234 SLC18A2 4件: Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10675 Valbenazine 1件: 8
235 SLC18A2 4件: Synaptic vesicle cycle, Serotonergic synapse, Dopaminergic synapse, Parkinson disease D10701 Deutetrabenazine 1件: 8
236 CACNA1B 12件: MAPK signaling pathway, Synaptic vesicle cycle, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Type II diabetes mellitus, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Nicotine addiction D01173 Cilnidipine 1件: 67
237 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine 1件: 6
238 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine 2件: 50, 81
239 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
240 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
241 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem 3件: 51, 58, 86
242 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine 2件: 70, 86
243 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil 3件: 96, 140, 167
244 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine 1件: 67
245 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine 1件: 90
246 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil 3件: 96, 140, 167
247 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
248 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem 3件: 51, 58, 86
249 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline 2件: 58, 272
250 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
251 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem 3件: 51, 58, 86
252 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine 2件: 70, 86
253 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline 2件: 58, 272
254 CACNA1C 19件: MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine 1件: 226
255 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00349 Isradipine 1件: 6
256 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00437 Nifedipine 2件: 50, 81
257 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00537 Topiramate 6件: 6, 97, 140, 144, 156, 193
258 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
259 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00616 Diltiazem 3件: 51, 58, 86
260 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00617 Nicardipine 2件: 70, 86
261 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D00619 Verapamil 3件: 96, 140, 167
262 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01173 Cilnidipine 1件: 67
263 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D01908 Nilvadipine 1件: 90
264 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02356 Verapamil 3件: 96, 140, 167
265 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
266 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D03830 Diltiazem 3件: 51, 58, 86
267 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D05442 Perhexiline 2件: 58, 272
268 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
269 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D07845 Diltiazem 3件: 51, 58, 86
270 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08270 Nicardipine 2件: 70, 86
271 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08340 Perhexiline 2件: 58, 272
272 CACNA1D 18件: MAPK signaling pathway, Vascular smooth muscle contraction, Tight junction, Retrograde endocannabinoid signaling, Glutamatergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, GnRH secretion, Type II diabetes mellitus, Growth hormone synthesis, secretion and action, Prion disease, Pathways of neurodegeneration - multiple diseases, Hypertrophic cardiomyopathy D08441 Propiverine 1件: 226